retatrutide type 1 diabetes In the News... Tzield, Retatrutide, New Clues About and more! Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide

It has the longer safety record with cardiovascular outcomes data now extending beyond 5 years and is widely available

However, robust clinical trial evidence is lacking, and current NICE guidance does not recommend GLP-1 agonists for treating alcohol use disorder

Among patients with type 2 diabetes, discontinuation remained high at 46.5% within the first year

People with preexisting GI symptoms may be more prone to discomfort or intolerance, though responses vary, and formal evidence is limited

For rapidly spreading redness, significant swelling, severe pain, or fever at an injection site, seek same-day assessment by contacting NHS 111 or your GP